Cargando…
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma gly...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700974/ https://www.ncbi.nlm.nih.gov/pubmed/36434633 http://dx.doi.org/10.1186/s12933-022-01652-z |
_version_ | 1784839436475826176 |
---|---|
author | Puig-Jové, Carlos Julve, Josep Castelblanco, Esmeralda Julián, M Teresa Amigó, Núria Andersen, Henrik U Ahluwalia, Tarunveer S Rossing, Peter Mauricio, Dídac Jensen, Magnus T Alonso, Núria |
author_facet | Puig-Jové, Carlos Julve, Josep Castelblanco, Esmeralda Julián, M Teresa Amigó, Núria Andersen, Henrik U Ahluwalia, Tarunveer S Rossing, Peter Mauricio, Dídac Jensen, Magnus T Alonso, Núria |
author_sort | Puig-Jové, Carlos |
collection | PubMed |
description | BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. METHODS: We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e′≥12 or E/e′ 8–12 + volume of the left atrium > 34 ml/m2. To identify a metabolic profile associated with the presence of subclinical myocardial dysfunction, a multivariate supervised model of classification based on least squares regression (PLS-DA regression) was performed. RESULTS: One-hundred forty-six subjects had diastolic dysfunction and 18 systolic dysfunction. Compared to the control group, patients with myocardial dysfunction had longer duration of diabetes (p = 0.005), and higher BMI (p = 0.013), serum NTproBNP concentration (p = 0.001), systolic blood pressure (p < 0.001), albuminuria (p < 0.001), and incidence of advanced retinopathy (p < 0.001). The supervised classification model identified a specific pattern associated with myocardial dysfunction, with a capacity to discriminate patients with myocardial dysfunction from controls. PLS-DA showed that triglyceride-rich lipoproteins (TGRLs), such as VLDL (total VLDL particles, large VLDL subclass and VLDL-TG content) and IDL (IDL cholesterol content), as well as the plasma concentration of GlycA, were associated with the presence of subclinical myocardial dysfunction. CONCLUSION: Proatherogenic TGRLs and the proinflammatory biomarker Glyc A are strongly associated to myocardial dysfunction in T1DM. These findings suggest a pivotal role of TGRLs and systemic inflammation in the development of subclinical myocardial dysfunction in T1DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01652-z. |
format | Online Article Text |
id | pubmed-9700974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97009742022-11-27 The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus Puig-Jové, Carlos Julve, Josep Castelblanco, Esmeralda Julián, M Teresa Amigó, Núria Andersen, Henrik U Ahluwalia, Tarunveer S Rossing, Peter Mauricio, Dídac Jensen, Magnus T Alonso, Núria Cardiovasc Diabetol Research BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. METHODS: We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e′≥12 or E/e′ 8–12 + volume of the left atrium > 34 ml/m2. To identify a metabolic profile associated with the presence of subclinical myocardial dysfunction, a multivariate supervised model of classification based on least squares regression (PLS-DA regression) was performed. RESULTS: One-hundred forty-six subjects had diastolic dysfunction and 18 systolic dysfunction. Compared to the control group, patients with myocardial dysfunction had longer duration of diabetes (p = 0.005), and higher BMI (p = 0.013), serum NTproBNP concentration (p = 0.001), systolic blood pressure (p < 0.001), albuminuria (p < 0.001), and incidence of advanced retinopathy (p < 0.001). The supervised classification model identified a specific pattern associated with myocardial dysfunction, with a capacity to discriminate patients with myocardial dysfunction from controls. PLS-DA showed that triglyceride-rich lipoproteins (TGRLs), such as VLDL (total VLDL particles, large VLDL subclass and VLDL-TG content) and IDL (IDL cholesterol content), as well as the plasma concentration of GlycA, were associated with the presence of subclinical myocardial dysfunction. CONCLUSION: Proatherogenic TGRLs and the proinflammatory biomarker Glyc A are strongly associated to myocardial dysfunction in T1DM. These findings suggest a pivotal role of TGRLs and systemic inflammation in the development of subclinical myocardial dysfunction in T1DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01652-z. BioMed Central 2022-11-24 /pmc/articles/PMC9700974/ /pubmed/36434633 http://dx.doi.org/10.1186/s12933-022-01652-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Puig-Jové, Carlos Julve, Josep Castelblanco, Esmeralda Julián, M Teresa Amigó, Núria Andersen, Henrik U Ahluwalia, Tarunveer S Rossing, Peter Mauricio, Dídac Jensen, Magnus T Alonso, Núria The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title | The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title_full | The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title_fullStr | The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title_full_unstemmed | The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title_short | The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
title_sort | novel inflammatory biomarker glyca and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700974/ https://www.ncbi.nlm.nih.gov/pubmed/36434633 http://dx.doi.org/10.1186/s12933-022-01652-z |
work_keys_str_mv | AT puigjovecarlos thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT julvejosep thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT castelblancoesmeralda thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT julianmteresa thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT amigonuria thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT andersenhenriku thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT ahluwaliatarunveers thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT rossingpeter thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT mauriciodidac thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT jensenmagnust thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT alonsonuria thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT puigjovecarlos novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT julvejosep novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT castelblancoesmeralda novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT julianmteresa novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT amigonuria novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT andersenhenriku novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT ahluwaliatarunveers novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT rossingpeter novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT mauriciodidac novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT jensenmagnust novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus AT alonsonuria novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus |